Vitalant – FDA 483, Jun 9, 2026

Vitalant in Minot, ND, was cited for failing to maintain adequate quality control and general records during an FDA inspection. The firm did not thoroughly investigate multiple deviations concerning overdrawn white blood units, neglecting to identify root causes or the specific collection equipment involved. This indicates a significant deficiency in their deviation management and record-keeping practices.